For nearly 50 years, the Hart-Scott-Rodino Act has given antitrust enforcers a chance to review deals above a certain value before they can close. What happens when the government concludes a transaction was structured intentionally to slip past that review entirely?
Managing partner Jeny Maier and Lexi Michaud of Fried Frank speak with Evan Miller of Vinson & Elkins about HSR Act avoidance and the FTC’s record-setting $12 million settlement with Edwards Lifesciences and Genesis MedTech over Edwards Lifesciences’s acquisition of JC Medical from Genesis. They discuss how the JC Medical deal was valued and structured, how the parties’ failure to file played a role in the FTC’s separate challenge to Edwards’s contemporaneous JenaValve acquisition, what deal teams should consider when assessing a transaction close to the HSR threshold, what the settlement signals about the FTC’s current approach to premerger notification enforcement, and more.
Watch below or on the Our Curious Amalgam website.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
